股異動 | 科濟藥業(2171.HK)漲超5%盤中再創新高 CAR-T候選產品研發進展領先全球
格隆匯9月23日丨科濟藥業(2171.HK)現漲5.11%,盤中高見49.8港元再度刷新歷史高價,總市值超275億港元。公司20日公吿,已於2021年歐洲腫瘤內科學會大會(“2021年ESMO大會”)以口頭報吿形式呈列發佈CT041(一種靶向CLDN18.2自體CAR-T候選產品)研究者發起的試驗的進展。科濟自主研發的CT041為全球唯一獲得IND許可的靶向CLDN18.2的CAR-T細胞,目前在中國和美國進行臨牀試驗。目前,科濟藥業已佈局該靶點CAR-T療法和單抗產品,先發優勢明顯,特別是CAR-T候選產品研發進展領先全球,是唯一獲得IND臨牀實驗許可的品種。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.